Abilify Related Published Studies
Well-designed clinical trials related to Abilify (Aripiprazole)
Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials. [2009.09]
Focus on Aripiprazole: A Review of its use in Child and Adolescent Psychiatry. [2009.08]
Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. [2009.08]
A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder. [2009.07]
UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study). [2009.06]
Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. [2009.05.15]
Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study. [2009.05]
Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial. [2009.05]
Subjective, cognitive/psychomotor, and physiological effects of aripiprazole in Chinese light and heavy smokers. [2009.04.01]
Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. [2009.04]
Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. [2009.04]
A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. [2009.04]
A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. [2009.03.15]
Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. naltrexone. [2009.03]
Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol. [2009.02]
Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission. [2009.02]
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. [2009.02]
Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. [2009.01]
A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer's, vascular, or mixed dementia. [2009.01]
Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. [2009.01]
An Open-Label Assessment of Aripiprazole in the Treatment of PTSD. [2009]
The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). [2008.12.22]
Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. [2008.12]
Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. [2008.12]
Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care. [2008.12]
Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. [2008.12]
Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trial. [2008.12]
A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. [2008.11]
Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm--possible influence of self-control. [2008.11]
Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. [2008.10]
Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care: results from the STAR study. [2008.08]
A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. [2008.07]
Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. [2008.05]
Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. [2008.05]
Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study. [2008.05]
Effects of aripiprazole on subjective and physiological responses to alcohol. [2008.04]
Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. [2008.04]
Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care. [2008.03.26]
Aripiprazole Augmentation in Clozapine-Treated Patients With Refractory Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial. [2008.03.18]
Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. [2007.12]
Aripiprazole in juvenile bipolar disorder comorbid with attention-deficit/hyperactivity disorder: an open clinical trial. [2007.10]
An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression. [2007.10]
Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. [2007.10]
A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA). [2007.10]
A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. [2007.10]
Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. [2007.09]
Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. [2007.09]
A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. [2007.06.05]
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. [2007.06]
Aripiprazole: pharmacology and evidence in bipolar disorder. [2007.05]
Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials. [2007.05]
Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up. [2007.05]
An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression. [2007.03.06]
Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. [2007.02]
Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. [2007.01]
Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. [2007]
The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance. [2007]
Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. [2006.12]
Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. [2006.11.16]
Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. [2006.10.21]
Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. [2006.07]
Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. [2006.05]
A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). [2006.05]
A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. [2006.04]
An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. [2006.02]
Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. [2006.01.09]
An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression. [2006]
Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study. [2005.10]
Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. [2005.09]
Aripiprazole, a novel atypical antipsychotic drug. [2004.02]
Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. [2004.02]
A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. [2004]
Aripiprazole. [2003.12.01]
Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. [2003.12]
Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. [2003.09]
A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. [2003.09]
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. [2003.07]
Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. [2003.04]
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. [2002.09]
Spontaneous brain magnetic activity in schizophrenia patients treated with aripiprazole. [1998]
Well-designed clinical trials possibly related to Abilify (Aripiprazole)
Effectiveness of second-generation antipsychotics with acute-phase schizophrenia. [2009.08]
Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. [2009.07.29]
A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. [2009.04]
Results of phase 3 of the CATIE schizophrenia trial. [2009.01]
One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia. [2008.12]
Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. [2008.05]
Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. [2008.04]
A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. [2008.02]
A Review of Sensitivity and Tolerability of Antipsychotics in Patients With Bipolar Disorder or Schizophrenia: Focus on Somnolence. [2008.01.16]
Pathophysiology and treatment of psychosis in Parkinson's disease: a review. [2008]
Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials. [2007.11]
Efficacy and Safety of Donepezil in Patients with Schizophrenia or Schizoaffective Disorder: Significant Placebo/Practice Effects in a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. [2007.07.11]
Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. [2007.06]
Are There Any Differences in the Efficacy among Second Generation Antipsychotics in the Treatment of Schizophrenia and Related Disorders? [2007.04]
Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. [2006.09]
Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. [2006.04]
Extrapyramidal side effects with atypical neuroleptics in bipolar disorder. [2006.03]
Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. [2005.12]
Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. [2005.10.19]
Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder. [2005.09.15]
|
